Interplay between hepatitis B virus and the innate immune responses: Implications for new therapeutic strategies

Virologica Sinica

Volumn 29, Issue 1, 2014, Pages 17-24

  Chen, Jieliang ^a   Yuan, Zhenghong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

antiviral approaches; HBV; innate immunity; interferon; viral evasion

Indexed keywords

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

EID: 84895076131     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-014-3412-3     Document Type: Review

References (66)

1. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, and Levrero M. 2012. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest, 122: 529-537.
2. Bertoletti A and Ferrari C. 2012. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut, 61: 1754-1764.
3. Chang J, Block T M, and Guo J T. 2012. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res, 96: 405-413.
4. Chen J, Zhang W, Lin J, Wang F, Wu M, Chen C, Zheng Y, Peng X, Li J, and Yuan Z. 2013. An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases. Mol Ther. doi:10.1038/mt.2013.212.
5. Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L, He J, Zheng Y, Chen C, Wang F, Hu Y, Zhou X, Wang C, Xu Y, Lu M, and Yuan Z. 2013. Hepatitis B virus polymerase impairs interferon-alpha-induced STA T activation through inhibition of importin-alpha5 and protein kinase C-delta. Hepatology, 57: 470-482.
6. Chen Y, Cheng G, and Mahato R I. 2008. RNAi for treating hepatitis B viral infection. Pharm Res, 25: 72-86.
7. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F, and Yuan Z. 2008. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol, 128: 400-408.
8. Cheng J, Imanishi H, Morisaki H, Liu W, Nakamura H, Morisaki T, and Hada T. 2005. Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFkappaB pathway in a human monocytic cell line, THP-1. J Hepatol, 43: 465-471.
9. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, and Heim M H. 2007. Inhibition of alpha interferon signaling by hepatitis B virus. J Virol, 81: 159-165.
10. Cooper A, Tal G, Lider O, and Shaul Y. 2005. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol, 175: 3165-3176.
11. Cradick T J, Keck K, Bradshaw S, Jamieson A C, and McCaffrey A P. 2010. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther, 18: 947-954.
12. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar R M, Brown D, Gilson R J, Tedder R J, Dusheiko G M, Jacobs M, Klenerman P, and Maini M K. 2009. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology, 137: 1289-1300.
13. Ebert G, Poeck H, Lucifora J, Baschuk N, Esser K, Esposito I, Hartmann G, and Protzer U. 2011. 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology, 141: 696-706, 706 e691-693.
14. Fernandez M, Quiroga J A, and Carreno V. 2003. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol, 84: 2073-2082.
15. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, and Ferrari C. 2009. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut, 58: 974-982.
16. Foster G R, Ackrill A M, Goldin R D, Kerr I M, Thomas H C, and Stark G R. 1991. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A, 88: 2888-2892.
17. Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, and Kremsdorf D. 2001. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol, 75: 2684-2691.
18. Gruffaz M, Testoni B, Luangsay S, Ait-Goughoulte M, Petit M-A, Ma H, Klumpp K, Javanbakht H, Durantel D, and Zoulim F. 2013. 378 hepatitis B core (hbc) protein is a key and very early negative regulator of the interferon response. Journal of Hepatology, 58: S155-S156.
19. Guidotti L G, Rochford R, Chung J, Shapiro M, Purcell R, and Chisari F V. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science, 284: 825-829.
20. Guidotti L G, Morris A, Mendez H, Koch R, Silverman R H, Williams B R, and Chisari F V. 2002. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol, 76: 2617-2621.
21. Guo H, Jiang D, Ma D, Chang J, Dougherty A M, Cuconati A, Block T M, and Guo J T. 2009. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol, 83: 847-858.
22. Guy C S, Mulrooney-Cousins P M, Churchill N D, and Michalak T I. 2008. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol, 82: 8579-8591.
23. Han Q, Zhang C, Zhang J, and Tian Z. 2011. Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS One, 6: e27931.
24. Han Q, Zhang C, Zhang J, and Tian Z. 2011. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology, 54: 1179-1189.
25. Han Q, Zhang C, Zhang J, and Tian Z. 2013. The role of innate immunity in HBV infection. Semin Immunopathol, 35: 23-38.
26. Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning C J, Langenkamp A, Falk C, Buning H, Rose-John S, and Protzer U. 2009. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology, 50: 1773-1782.
27. Isogawa M, Robek M D, Furuichi Y, and Chisari F V. 2005. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol, 79: 7269-7272.
28. Kosinska A D, Zhang E, Johrden L, Liu J, Seiz P L, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, and Roggendorf M. 2013. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog, 9: e1003391.
29. Kumar M, Jung S Y, Hodgson A J, Madden C R, Qin J, and Slagle B L. 2011. Hepatitis B Virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol, 85: 987-995.
30. Kwon H, and Lok A S. 2011. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol, 8: 275-284.
31. Lan P, Zhang C, Han Q, Zhang J, and Tian Z. 2013. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance. Hepatology, 58: 73-85.
32. Lanford R E, Guerra B, Chavez D, Giavedoni L, Hodara V L, Brasky K M, Fosdick A, Frey C R, Zheng J, Wolfgang G, Halcomb R L, and Tumas D B. 2013. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology, 144: 1508-1517.
33. Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, and Mansell A. 2011. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol, 55: 762-769.
34. Li J, Lin S, Chen Q, Peng L, Zhai J, Liu Y, and Yuan Z. 2010. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol, 84: 6387-6399.
35. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X, and Yuan Z. 2013. Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. Nat Immunol, 14: 793-803.
36. Lu H L, and Liao F. 2013. Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Immunol, 191: 3264-3276.
37. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, and Zoulim F. 2009. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology, 51: 63-72.
38. Lutgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann J H, Pollok J M, Lohse A W, Petersen J, and Dandri M. 2011. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology, 140: 2074-2083, 2083 e2071-2072.
39. Mao R, Nie H, Cai D, Zhang J, Liu H, Yan R, Cuconati A, Block T M, Guo J T, and Guo H. 2013. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog, 9: e1003494.
40. Meng Z, Xu Y, Wu J, Tian Y, Kemper T, Bleekmann B, Roggendorf M, Yang D, and Lu M. 2008. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J Virol Methods, 150: 27-33.
41. Muller C, and Zielinski C C. 1990. Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis. Hepatology, 12: 1118-1124.
42. Nguyen D H, Gummuluru S, and Hu J. 2007. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol, 81: 4465-4472.
43. Nguyen D H, Ludgate L, and Hu J. 2008. Hepatitis B virus-cell interactions and pathogenesis. J Cell Physiol, 216: 289-294.
44. Op den Brouw M L, Binda R S, van Roosmalen M H, Protzer U, Janssen H L, van der Molen R G, and Woltman A M. 2009. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology, 126: 280-289.
45. Pagliaccetti N E, Chu E N, Bolen C R, Kleinstein S H, and Robek M D. 2010. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology, 401: 197-206.
46. Protzer U, Maini M K, and Knolle P A. 2012. Living in the liver: hepatic infections. Nat Rev Immunol, 12: 201-213.
47. Rang A, Gunther S, and Will H. 1999. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol, 31: 791-799.
48. Revill P, and Yuan Z. 2013. New insights into how HBV manipulates the innate immune response to establish acute and persistent infection. Antivir Ther, 18: 1-15.
49. Robek M D, Boyd B S, and Chisari F V. 2005. Lambda interferon inhibits hepatitis B and C virus replication. J Virol, 79: 3851-3854.
50. Turelli P, Mangeat B, Jost S, Vianin S, and Trono D. 2004. Inhibition of hepatitis B virus replication by APOBEC3G. Science, 303: 1829.
51. Vincent I E, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U, and Chemin I. 2011. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One, 6: e26315.
52. Visvanathan K, Skinner N A, Thompson A J, Riordan S M, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, Desmond P, and Locarnini S. 2007. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology, 45: 102-110.
53. Wang H, and Ryu W S. 2010. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog, 6: e1000986.
54. Wang Q, Zhou J, Zhang B, Tian Z, Tang J, Zheng Y, Huang Z, Tian Y, Jia Z, Tang Y, van Velkinburgh J C, Mao Q, Bian X, Ping Y, Ni B, and Wu Y. 2013. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis. PLoS Pathog, 9: e1003410.
55. Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y, and Yuan Z. 2013. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol, 190: 5142-5151.
56. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Wang Y, Wen C, Wu Q, Shi W, and Zhong H. 2010. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol, 185: 1158-1168.
57. Wieland S, Thimme R, Purcell R H, and Chisari F V. 2004. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A, 101: 6669-6674.
58. Wieland S F, Guidotti L G, and Chisari F V. 2000. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol, 74: 4165-4173.
59. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, and Schlaak J F. 2007. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology, 46: 1769-1778.
60. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa J P, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, and Schlaak J F. 2009. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology, 49: 1132-1140.
61. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, and Yuan Z. 2009. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol, 46: 2640-2646.
62. Yu S, Chen J, Wu M, Chen H, and Yuan Z. 2010. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol, 91: 2080-2090.
63. Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Iqbal J, Hussain M M, Balschun K, Rocken C, Arlt A, Gunther R, Hampe J, Schreiber S, Baron J L, Moody D B, Liang T J, and Blumberg R S. 2012. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med, 18: 1060-1068.
64. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak J F, Roggendorf M, and Lu M. 2012. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol, 57: 522-528.
65. Zimmerman K A, Fischer K P, Joyce M A, and Tyrrell D L. 2008. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol, 82: 8013-8021.
66. Zoulim F. 2012. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res, 96: 256-259.